Latest Insider Transactions at Lexeo Therapeutics, Inc. (LXEO)
This section provides a real-time view of insider transactions for Lexeo Therapeutics, Inc. (LXEO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Lexeo Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Lexeo Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$40,000
$8.1 P/Share
|
|
Oct 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Sep 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$50,000
$10.65 P/Share
|
|
Sep 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Aug 12
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$55,000
$11.53 P/Share
|
|
Aug 12
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Jul 11
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,031
-9.43%
|
$504,558
$18.06 P/Share
|
|
Jul 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,969
-7.82%
|
$431,504
$16.65 P/Share
|
|
Jul 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.77%
|
$10,000
$2.33 P/Share
|
|
Jun 12
2024
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+50.0%
|
-
|
|
Jun 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.43%
|
$85,000
$17.74 P/Share
|
|
Jun 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.77%
|
$10,000
$2.33 P/Share
|
|
May 13
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.85%
|
$65,000
$13.22 P/Share
|
|
May 13
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.77%
|
$10,000
$2.33 P/Share
|
|
Feb 02
2024
|
Eric Adler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,875
+50.0%
|
-
|
|
Jan 05
2024
|
Jenny Robertson Chief Legal and Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,750
+50.0%
|
-
|
|
Jan 05
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+20.4%
|
-
|
|
Nov 07
2023
|
Paul Mc Cormac Chief Technical Officer |
BUY
Conversion of derivative security
|
Direct |
3,191
+15.54%
|
-
|
|
Nov 07
2023
|
Omega Fund Vi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
454,545
+17.4%
|
$4,999,995
$11.0 P/Share
|
|
Nov 07
2023
|
Omega Fund Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,703,078
+32.22%
|
-
|
|
Nov 07
2023
|
Longitude Capital Partners Iv, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
454,545
+15.04%
|
$4,999,995
$11.0 P/Share
|
|
Nov 07
2023
|
Longitude Capital Partners Iv, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,112,555
+31.56%
|
-
|
|
Nov 07
2023
|
Invest A/S Lundbeckfond > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
227,272
+11.02%
|
$2,499,992
$11.0 P/Share
|
|
Nov 07
2023
|
Invest A/S Lundbeckfond > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,608,687
+32.57%
|
-
|